Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
•
Hepatology
When treating fatty liver disease with resmetirom, how often should a FibroScan be repeated to assess treatment response?
Related Questions
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?
Can fatty liver disease present with elevations in alkaline phosphatase without other liver enzyme elevations (AST and ALT)?
How do you decide between bariatric surgery and a GLP-1 receptor agonist for patients with metabolic dysfunction-associated steatotic liver disease who have not met weight loss goals after six months of lifestyle interventions?
Should orlistat be avoided in patients with a history of kidney stones?
Can procalcitonin be used as a marker for endothelial dysfunction emanating from chronic inflammation of obesity?
Do you recommend restarting GLP-1RA after bariatric surgery if they tolerated it before the surgery?
In patients with iron deficiency due to history of gastric bypass or IBD, would you consider oral iron therapy if the iron deficiency anemia is mild?
What do you recommend to your patients to prevent muscle loss when prescribing a GLP-1 agonist for weight loss?
In patients with severe obesity, do you recommend a trial of GLP 1 R agonist therapy prior to bariatric surgery?
